Literature DB >> 27821456

Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Deanna J Buehrle1, Ryan K Shields1,2, Lloyd G Clarke3, Brian A Potoski3, Cornelius J Clancy4,2,5, M Hong Nguyen1,2.   

Abstract

We reviewed 37 patients treated for bacteremia due to carbapenem-resistant (CR) Pseudomonas aeruginosa Although 65% of isolates were multiple-drug resistant, therapeutic options were available, as all were susceptible to ≥1 antibiotic. A total of 92% of patients received active antimicrobial therapy, but only 57% received early active therapy (within 48 h). Fourteen-day mortality was 19%. Microbiologic failure occurred in 29%. The Pitt bacteremia score (P = 0.046) and delayed active therapy (P = 0.027) were predictive of death and microbiologic failure, respectively.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; bacteremia; carbapenem resistance; mortality

Mesh：

Substances：

Year:  2016        PMID： 27821456      PMCID： PMC5192105          DOI： 10.1128/AAC.01243-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

2.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

3.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome.

Authors:  Su Jin Jeong; Sang Sun Yoon; Il Kwon Bae; Seok Hoon Jeong; June Myung Kim; Kyungwon Lee
Journal:  Diagn Microbiol Infect Dis       Date:  2014-07-17       Impact factor: 2.803

5.  Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.

Authors:  Cristina Suárez; Carmen Peña; Laura Gavaldà; Fe Tubau; Adriana Manzur; M Angeles Dominguez; Miquel Pujol; Francesc Gudiol; Javier Ariza
Journal:  Int J Infect Dis       Date:  2010-03-11       Impact factor: 3.623

6.  Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.

Authors:  Eun-Jeong Joo; Cheol-In Kang; Young Eun Ha; Seung-Ji Kang; So Yeon Park; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  Microb Drug Resist       Date:  2011-03-07       Impact factor: 3.431

7.  Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).

Authors:  Helio S Sader; Mariana Castanheira; Robert K Flamm; Rodrigo E Mendes; David J Farrell; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2015-06-23       Impact factor: 2.803

8.  Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.

Authors:  Te-Din Huang; Catherine Berhin; Pierre Bogaerts; Youri Glupczynski
Journal:  J Antimicrob Chemother       Date:  2013-04-03       Impact factor: 5.790

Review 9.  Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.

Authors:  Yu Zhang; Xiao-Li Chen; Ai-Wei Huang; Su-Ling Liu; Wei-Jiang Liu; Ni Zhang; Xu-Zai Lu
Journal:  Emerg Microbes Infect       Date:  2016-03-23       Impact factor: 7.163

10.  Vital signs: carbapenem-resistant Enterobacteriaceae.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-08       Impact factor: 17.586
View more
  28 in total

Review 1.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

2.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

3.  The Economic Conundrum for Antibacterial Drugs.

Authors:  David M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

4.  Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network.

Authors:  Nathaniel J Rhodes; Jamie L Wagner; Susan L Davis; John A Bosso; Debra A Goff; Michael J Rybak; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections.

Authors:  Helen L Zhang; Leigh Cressman; Ebbing Lautenbach
Journal:  J Glob Antimicrob Resist       Date:  2021-11-12       Impact factor: 4.035

6.  5NosoAE: a web server for nosocomial bacterial antibiogram investigation and epidemiology survey.

Authors:  Chih-Chieh Chen; Yen-Yi Liu; Ya-Chu Yang; Chu-Yi Hsu
Journal:  Nucleic Acids Res       Date:  2022-05-25       Impact factor: 19.160

Review 7.  Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa in an endemic area: comparison with global data.

Authors:  Theodoros Karampatakis; Charalampos Antachopoulos; Athanassios Tsakris; Emmanuel Roilides
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-11       Impact factor: 3.267

8.  Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?

Authors:  Nicholas S Britt; David J Ritchie; Marin H Kollef; Carey-Ann D Burnham; Michael J Durkin; Nicholas B Hampton; Scott T Micek
Journal:  Am J Infect Control       Date:  2018-04-26       Impact factor: 2.918

9.  Multimodal Interventions to Prevent and Control Carbapenem-Resistant Enterobacteriaceae and Extended-Spectrum β-Lactamase Producer-Associated Infections at a Tertiary Care Hospital in Egypt.

Authors:  Noha A Kamel; Khaled M Elsayed; Mohamed F Awad; Khaled M Aboshanab; Mervat I El Borhamy
Journal:  Antibiotics (Basel)       Date:  2021-04-30

10.  Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis.

Authors:  Nicholas S Britt; David J Ritchie; Marin H Kollef; C A Burnham; Michael J Durkin; Nicholas B Hampton; Scott T Micek
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.